Adquey-Difamilast
Adquey (Difamilast) is a topical phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of atopic dermatitis (AD) in adult and pediatric patients aged 2 years and older. Adquey delivers targeted anti-inflammatory and antipruritic effects with a rapid onset of action, resulting in significant clinical improvement within the first week of treatment. Difamilast works by selectively inhibiting […]
Nereus-Tradipitant
Nereus (tradipitant) is a newly FDA‑approved oral neurokinin‑1 (NK‑1) receptor antagonist indicated for the prevention of vomiting induced by motion sickness in adults, representing the first new pharmacologic option for this condition in over 40 years; it works by selectively blocking substance P–mediated activation of NK‑1 receptors in the brain to reduce motion‑induced vomiting, and […]
Zycubo-Copper Histidinate
Zycubo (copper histidinate) is a bioavailable copper replacement therapy approved by the U.S. FDA in January 2026 as the first and only treatment for Menkes disease in pediatric patients. It is a rare X‑linked genetic disorder in which the body cannot absorb or transport copper properly, leading to severe neurodegeneration and early mortality. It is administered […]
Yartemlea-Narsoplimab-Wuug
Yartemlea is a fully human monoclonal antibody that selectively inhibits mannan-binding lectin–associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of the complement system. It is approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and pediatric patients aged two years and older. By blocking MASP-2, Yartemlea prevents […]
Nuzolvence-Zoliflodacin
Nuzolvence (zoliflodacin) is a first-in-class, oral antibacterial agent indicated for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older who meet weight requirements. Zoliflodacin belongs to a novel class of spiropyrimidinetrione antibiotics and inhibits bacterial type II topoisomerase enzymes, which are essential for DNA replication in Neisseria gonorrhoeae. This […]
Cardamyst-Etripamil
Cardamyst (etripamil) is a prescription intranasal therapy indicated for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a rapid-acting calcium channel blocker that slows conduction through the atrioventricular (AV) node, helping terminate abnormal cardiac electrical activity responsible for PSVT. Designed for self-administration at symptom onset, Cardamyst provides a […]
Myqorzo-Aficamten
Myqorzo (aficamten) is a prescription oral therapy indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults to improve functional capacity and reduce symptoms. It is a cardiac myosin inhibitor that binds to the motor protein myosin in the heart muscle, reducing excessive contractile force and decreasing left ventricular outflow tract obstruction that […]
Lerochol-Lerodalcibep-Liga
Lerochol is a novel cholesterol-lowering biologic developed to address unmet needs in the management of hypercholesterolemia. It is indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) levels in adults, including those with heterozygous familial hypercholesterolemia (HeFH). It is designed to target PCSK9-mediated pathways, thereby enhancing LDL receptor recycling and […]
Exdensur-Depemokimab-Ulaa
Exdensur (depemokimab-ulaa) is an ultra-long-acting biologic therapy indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every six months in addition to standard asthma medications to help reduce the frequency of asthma exacerbations. It is […]
Voyxact-Sibeprenlimab-Szsi
Voyxact® (sibeprenlimab-szsi) is an FDA-approved prescription medicine used to reduce proteinuria (protein in the urine) in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This approval is under the FDA’s accelerated approval pathway, based on the reduction of proteinuria. Its long-term impact on slowing kidney function decline is still being […]
